Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the ninth member of the proprotein convertase family and plays an important role in lipid metabolism. Its serum expression level can affect the concentration of cholesterol in the aorta, so it can be used as a biomarker of lipid metabolism. Creative BioMart Biomarker is capable to provide our customers with superior PCSK9 detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
PCSK9 is the ninth member of the proprotein convertase family and is expressed in many tissues and cells. The proprotein convertase are serine protease enzymes that functions in converting an inactive proprotein into an active form by cleavage. The main function of PCSK9 is autocatalysis, which converts proPCSK9 into active PCSK9. PCSK9 plays an important role in lipoprotein metabolism. PCSK9 binds to the epidermal growth factor-like repeat domain of the low density lipoprotein (LDL) receptor (LDLR). Under normal conditions, LDLR not bound to PCSK9 can be recycled to the cell surface, clearing lipoproteins from the circulation, mainly LDL, thereby reducing the concentration of LDL or LALR can be degraded by lysosomes. PCSK9, after binding to LALR through its prosefragment, internalizes with LDLR, induces a conformational change in LALR, resulting in its inability to form a closed conformation, reducing normal circulation of LDLR and increasing LALR lysosomal degradation. Thus expression and release of PCSK9 in the circulation increases the concentration of plasma LDL-C. If PCSK9 is blocked, more LDLR is recycled and present on the cell surface to remove LDL from the extracellular fluid, thus blocking PCSK9 can lower the concentration of blood LDL. In mice lacking PCSK9, the accumulation of cholesteryl esters in the aorta is significantly reduced. Conversely, overexpression of PCSK9 induces excessive atherosclerosis. Therefore, PCSK9 acts as a lipid metabolism maker to detect cholesterol homeostasis.
Figure 1. LDLR recycling pathway.
Application of PCSK9
- Serum, plasma levels of PCSK9 can be used as a biomarker to monitor cholesterol homeostasis and predict the risk of atherosclerosis and cardiovascular events.
Our Advantages
- Accept a wide range of sample types
- Provide multiple detection methods
- Ensure high sensitivity for detecting PCSK9 in different samples
- Ensure high accuracy and repeatable PCSK9 detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of PCSK9 Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the PCSK9 detection procedure to ensure high sensitivity, high accuracy and repeatable PCSK9 detection.
Please feel free to contact us if you would like to know more about PCSK9 detection. At Creative BioMart Biomarker, we not only provide high-quality PCSK9 detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
References:
- Page, M.M.; Watts, G.F. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes Obes Metab. 2018, 20(2): 270-282.
- Farnier, M. PCSK9: From discovery to therapeutic applications. Arch Cardiovasc Dis. 2014, 107(1): 58-66.
- Weinreich, M.; Frishman, W.H. Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev. 2014, 22(3): 140-6.
